116 studies found for:    IGF1R
Show Display Options
Rank Status Study
1 Completed Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: AVE1642;   Drug: Velcade
2 Completed Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Genetic: Protein expression by immunohistochemistry and immunofluorescence
3 Terminated Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: AVE1642;   Drug: Fulvestrant
4 Suspended Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Condition: Advanced Refractory Solid Tumors
Intervention: Drug: PL225B
5 Completed Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Condition: Solid Tumors
Intervention: Drug: BIIB022
6 Completed A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
Conditions: Askin's Tumors;   Desmoplastic Small Round Cell Tumors;   Estraosseous Ewing's Tumor;   Ewing's Family Tumor;   Ewing's Sarcoma;   Primitive Neuroectodermal Tumors (PNETs);   Sarcoma
Intervention: Drug: AMG 479
7 Completed A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: BIIB022 With Paclitaxel and Carboplatin
8 Withdrawn Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: IGF-1R inhibitor OSI-906;   Drug: erlotinib hydrochloride;   Drug: goserelin;   Drug: letrozole
9 Active, not recruiting Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Biological: cixutumumab;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
10 Terminated Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
Condition: Liver Carcinoma
Interventions: Drug: AVE1642;   Drug: sorafenib;   Drug: erlotinib
11 Terminated
Has Results
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
Conditions: Recurrent Adrenocortical Carcinoma;   Stage III Adrenocortical Carcinoma;   Stage IV Adrenocortical Carcinoma
Interventions: Biological: IMC-A12;   Drug: mitotane
12 Terminated
Has Results
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Conditions: Carcinoma, Squamous Cell;   Carcinoma, Adenosquamous;   Carcinoma, Large Cell;   Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 (Figitumumab);   Drug: Carboplatin;   Drug: Paclitaxel
13 Completed A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: RG1507
14 Completed A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
Condition: Solid Tumors
Intervention: Drug: AXL1717
15 Recruiting Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Conditions: Breast Cancer;   Brain Cancer;   Gastrointestinal Cancers;   Genitourinary Cancers;   Gynecologic Cancers;   Head and Neck Cancers;   Melanoma;   Thoracic Cancers
Intervention: Drug: IGF-Methotrexate
16 Completed Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Interventions: Drug: BIIB022;   Drug: Sorafenib
17 Completed A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AXL1717
18 Active, not recruiting MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Arm A: Pemetrexed Cisplatin;   Drug: Arm B Pemetrexed, Cisplatin and MK-0646
19 Recruiting Phase I/II Trial of the Safety, Tolerability, and Anti-tumor Efficacy of AXL1717 (Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
Conditions: Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma;   Anaplastic Ependymoma
Intervention: Drug: AXL1717
20 Active, not recruiting Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: cixutumumab;   Drug: octreotide acetate;   Drug: everolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years